Your browser doesn't support javascript.
A pilot trial of human amniotic fluid for the treatment of COVID-19.
Selzman, Craig H; Tonna, Joseph E; Pierce, Jan; Vargas, Camila; Skidmore, Chloe; Lewis, Giavonni; Hatton, Nathan D; Phillips, John D.
  • Selzman CH; Division of Cardiothoracic Surgery, University of Utah School of Medicine, 3C 127, 30 N 1900 E, Salt Lake City, UT, 84132, USA. craig.selzman@hsc.utah.edu.
  • Tonna JE; Division of Cardiothoracic Surgery, University of Utah School of Medicine, 3C 127, 30 N 1900 E, Salt Lake City, UT, 84132, USA.
  • Pierce J; Cell Therapy and Regenerative Medicine Program, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Vargas C; Division of Cardiothoracic Surgery, University of Utah School of Medicine, 3C 127, 30 N 1900 E, Salt Lake City, UT, 84132, USA.
  • Skidmore C; Division of Cardiothoracic Surgery, University of Utah School of Medicine, 3C 127, 30 N 1900 E, Salt Lake City, UT, 84132, USA.
  • Lewis G; Division of General Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Hatton ND; Pulmonary and Criticial Care Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
  • Phillips JD; Cell Therapy and Regenerative Medicine Program, University of Utah School of Medicine, Salt Lake City, UT, USA.
BMC Res Notes ; 14(1): 32, 2021 Jan 22.
Article in English | MEDLINE | ID: covidwho-1044064
ABSTRACT

OBJECTIVE:

Vertical transmission from SARS CoV-2-infected women is uncommon and coronavirus has not been detected in amniotic fluid. Human amniotic products have a broad immune-mediating profile. Observing that many COVID-19 patients have a profound inflammatory response to the virus, we sought to determine the influence of human amniotic fluid (hAF) on hospitalized patients with COVID-19.

RESULTS:

A 10-patient case series was IRB-approved to study the impact of hAF on hospitalized patients with documented COVID-19. Nine of the 10 patients survived to discharge, with one patient succumbing to the disease when enrolled on maximal ventilatory support and severe hypoxia. The study design was altered by the IRB such that the last 6 patients received higher dose of intravenous hAF. In this latter group, patients that had observed reductions in C-reactive protein were associated with improved clinical outcomes. No hAF-related adverse events were noted. Acknowledging some of the inherent limitations of this case series, these results inform and catalyze a larger scaled randomized prospective trial to further investigate hAF as a therapy for COVID-19. Trial Registration ClinicalTrials.gov NCT04319731; March 23, 2020.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Amniotic Fluid Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Pregnancy / Young adult Language: English Journal: BMC Res Notes Year: 2021 Document Type: Article Affiliation country: S13104-021-05443-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Amniotic Fluid Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged / Pregnancy / Young adult Language: English Journal: BMC Res Notes Year: 2021 Document Type: Article Affiliation country: S13104-021-05443-9